Inovio制药
1.47
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Inovio制药
Inovio制药公司致力于提供设计的DNA药物，以治疗和保护人们免受传染病、癌症和与人类乳头瘤病毒相关的疾病的伤害。其产品线包括VGX-3100、INO-3107、INO-5410、INO-4800和PENNVAX-GP。该公司由大卫·B·韦纳于1983年6月29日创立，总部设在宾夕法尼亚州普利茅斯会议。
Trade GPT
Similar Stocks
© 2025 Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.